Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial.

Camidge, D Ross; Bar, Jair; Horinouchi, Hidehito; Goldman, Jonathan; Moiseenko, Fedor; Filippova, Elena; Cicin, Irfan; Ciuleanu, Tudor; Daaboul, Nathalie; Liu, Chunling; Bradbury, Penelope; Moskovitz, Mor; Katgi, Nuran; Tomasini, Pascale; Zer, Alona; Girard, Nicolas; Cuppens, Kristof; Han, Ji-Youn; Wu, Shang-Yin; Baijal, Shobhit; Mansfield, Aaron S; Kuo, Chih-Hsi; Nishino, Kazumi; Lee, Se-Hoon; Planchard, David; Baik, Christina; Li, Martha; Ansell, Peter; Xia, Summer; Bolotin, Ellen; Looman, Jim; Ratajczak, Christine; Lu, Shun

Abstract

Telisotuzumab vedotin (Teliso-V) is a c-Met-directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase 2 LUMINOSITY trial (NCT03539536) aimed to identify the optimal c-Met protein-overexpressing non-small cell lung cancer (NSCLC) population for treatment with Teliso-V (stage 1) and expand the selected group for efficacy evaluation (stage 2). Stage 2 enrolled patients with non-squamous epidermal growth factor receptor (EGFR)-wildtype NSCLC.

Citation

Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6.

Type

Article